RNAZ - Transcode Therapeutics, Inc.
9.6
0.270 2.813%
Share volume: 11,008
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$9.33
0.27
0.03%
View ratios
| Fiscal Date | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 08-14-2024 | 11-14-2024 | 05-14-2025 | 11-14-2025 | |
| Assets | |||||
| Total Assets | 4.825 M | 3.936 M | 13.194 M | 5.227 M | |
| Current Assets | 4.386 M | 3.613 M | 13.044 M | 4.751 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 11.953 K | 322.436 K | 198.296 K | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 3.355 M | 1.876 M | 11.569 M | 2.836 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 64.581 K | 61.420 K | 38.131 K | 19.908 K | |
| Other Assets | 373.586 K | 262.096 K | 111.856 K | 455.726 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||
| Total Liabilities and shareholders’ equity | 4.825 M | 3.936 M | 13.194 M | 5.227 M | |
| Total liabilities | 3.502 M | 2.284 M | 2.902 M | 3.801 M | |
| Total current liabilities | 3.502 M | 2.284 M | 2.510 M | 2.968 M | |
| Accounts Payable | 3.275 M | 2.131 M | 2.510 M | 2.968 M | |
| Other liabilities | 0.000 | 0.000 | 392.000 K | 832.875 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 392.000 K | 832.875 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.322 M | 1.652 M | 10.293 M | 1.426 M | |
| Common stock | 56.256 M | 58.908 M | 85.580 M | 85.846 M | |
| Retained earnings | -54.934 M | -57.255 M | -75.287 M | -84.420 M |